Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Government Grants Galore And Other New Funding Sources

Executive Summary

While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.


Related Content

Incubator Addition: Arix CIO On Why Fund Added VelosBio To Portfolio
Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B
Opioids Could Become Bioterror Weapons, US Fears; BARDA Funds Countermeasures
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
KSQ Comes Out Of Stealth Mode With $76m And Meeker As CEO
Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?
AstraZeneca In Buy Now, Pay In Full Later Deal For Majority Acerta Stake
Investors Find Opportunity In Tau-Targeting Biopharmas
BioNotebook: Vertex/BioAxone and four other deals; three VC updates, three public offerings
Texas thinks big as it provides $81mn to cancer research, drug development and venture support


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts